Allergan plc (AGN)

NYSE - NYSE Real Time Price. Currency in USD
230.80-6.99 (-2.94%)
At close: 4:04 PM EDT
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev Close237.79
Bid231.25 x 100
Ask232.50 x 500
Day's Range229.61 - 238.13
52wk Range195.50 - 322.68
1y Target EstN/A
Market Cap91.39B
P/E Ratio (ttm)21.97
Avg Vol (3m)2,998,007
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Market Realist52 minutes ago

    Teva Has a Targeted Strategy to Expand in Major Growth Markets

    In Russia, Teva Pharmaceutical has created a strong portfolio of about 300 products and has been extensively developing its research pipeline.

  • MarketWatch4 hours ago

    Biotech stocks have plenty of catalysts around the corner

    While buyouts are looming, political bashing of drug prices has died down, says Michael Brush.

  • PR Newswire23 hours ago

    Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals

    DUBLIN, Sept. 29, 2016 /PRNewswire/ -- Allergan plc (AGN), today issued the following statement regarding ongoing litigation on patents related to NAMENDA XR® (memantine hydrochloride) extended release capsules following announcement of FDA final ANDA approval by Lupin. One of the licensed patent families covering Namenda XR has been held invalid by the Federal District Court for the District of Delaware.  That decision is under appeal to the U.S. Court of Appeals for the Federal Circuit. The Company will defend the validity of these patents on appeal and believes that its arguments on appeal are substantial and meritorious.